Corcept Resubmits Relacorilant NDA for Cushing’s Syndrome After FDA Requests Additional Data
Event summary
- Corcept Therapeutics plans to resubmit its New Drug Application (NDA) for relacorilant as a treatment for Cushing’s syndrome in the coming weeks.
- The FDA requested additional analyses of the NDA data following the issuance of a complete response letter.
- The FDA has indicated a Prescription Drug User Fee Act (PDUFA) date six months after the resubmission.
- Relacorilant is designed to modulate the effects of cortisol, addressing symptoms of hypercortisolism such as hypertension, obesity, and diabetes.
The big picture
Corcept’s resubmission of the NDA for relacorilant reflects the FDA’s stringent requirements for new drug approvals, particularly in the endocrine space. The company’s focus on cortisol modulation aligns with broader industry trends toward targeted therapies for metabolic and endocrine disorders. The outcome of this resubmission will be critical for Corcept’s growth strategy, as it seeks to expand its portfolio beyond its existing approved drugs, Korlym and Lifyorli.
What we're watching
- Regulatory Timing
- The pace at which the FDA reviews the resubmitted NDA will determine the commercialization timeline for relacorilant.
- Clinical Efficacy
- The success of relacorilant hinges on its ability to demonstrate superior efficacy and safety compared to existing treatments.
- Market Positioning
- How Corcept positions relacorilant in the competitive landscape of cortisol modulators will impact its market adoption.
Related topics